Becton, Dickinson and Company BDX
NYSE · Healthcare · Medical - Instruments & Supplies
$212.78
Close on Fri, 20 Nov 2026 · market value $58B
What the price is betting on
Below its recordAt $213, the price assumes revenue shrinks about 0.3% a year for five years, from $19.5B to about $19.1B by FY2031. That is less than what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 6.6% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than BDX? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$233
Base
$263
Bull
$296
Today $213
- Bear $233. Cash flow grows 1% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $263. Cash flow grows 3% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $296. Cash flow grows 5% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2027$19.4B$19.7B, on the path
- FY2028$19.3B$20.6B, on the path
- FY2029$19.3B$21.4B, on the path
- FY2030$19.2B$22B, on the path
- FY2031$19.1B$22.9B, on the path
Each year's revenue at −0.3% growth from $19.5B in FY2026.
At a glance
Healthcare · Medical - Instruments & Supplies · listed on NYSE
- Revenue, FY2026
- $19.5B
- Growth, 3 years a year
- 0.1%
- Cash margin
- 14%
- Net debt
- $15.6B
- Shares, 3-year change
- −2.9%
- Dividend yield
- 2%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.